论文部分内容阅读
本文检测85例原发性肝癌患者AFP、AIF、SF阳性率依次为84.7％、76.5％、54.1,AFP与AIF或SF联检可使阳性率分别提高至97.6％、94.1％。在AFP阴性或低浓度时,AIF与SF联检可弥补AFP之不足。测定36例肺癌患者CEA、AIF、SF阳性率分别为72.2％、77.8％、72.2％,三项指标联检阳性率可达100％。由此说明多项标志物联检对提高恶性肿瘤诊断的阳性率和特异性具有重要临床价值。
The positive rates of AFP, AIF and SF in 85 patients with primary liver cancer were 84.7%, 76.5% and 54.1, respectively. The combined rate of AFP and AIF or SF increased the positive rate to 97.6% and 94.1%, respectively. When AFP is negative or at a low concentration, the combination of AIF and SF can compensate for the deficiency of AFP. The positive rates of CEA, AIF, and SF in 36 lung cancer patients were 72.2%, 77.8%, and 72.2%, respectively. The positive rate of the three indexes was 100%. This shows that multi-marker biomarkers have important clinical value in improving the positive rate and specificity of diagnosis of malignant tumors.